GlassScriptPhysician profile
Marrey Ruby Laxa Quizon
NPI 1720617194
$1,942.98
in general payments reported to CMS, 2019-2025
21 companies · $1,794 in 2025
The $1,794 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $18.47 · 2024: $131 · 2025: $1,794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,942.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $325.95 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.52 | 2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $206.77 | 2025 | Lokelma, Farxiga |
| Apellis Pharmaceuticals, INC. | $163.34 | 2025 | Empaveli |
| Aurinia Pharma U.S., INC. | $152.06 | 2024-2025 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $142.90 | 2025 | Acthar |
| Glaxosmithkline, LLC. | $124.59 | 2025 | Benlysta |
| Calliditas Therapeutics US INC. | $115.41 | 2025 | Tarpeyo |
| Vifor Pharma, INC. | $110.92 | 2025 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $59.83 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $57.41 | 2025 | Jynarque |
| Alnylam Pharmaceuticals INC. | $32.18 | 2025 | Oxlumo |
| Takeda Pharmaceuticals U.S.A., INC. | $31.15 | 2025 | Livtencity |
| Akebia Therapeutics INC | $27.82 | 2025 | Vafseo |
| Scpharmaceuticals INC. | $26.43 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $25.99 | 2025 | Purified Cortrophin Gel |
| Opko Pharmaceuticals, LLC | $24.97 | 2025 | Rayaldee |
| Veloxis Pharmaceuticals, INC. | $23.17 | 2025 | Envarsus |
| Novo Nordisk INC | $23.09 | 2025 | Rivfloza |
| Travere Therapeutics, INC. | $23.01 | 2025 | |
| Seagen INC. | $18.47 | 2023 | Adcetris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marrey Ruby Quizon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.